Abstract
Amphetamine (AMPH) is known to raise extracellular dopamine (DA) levels by inducing stimulation-independent DA efflux via reverse transport through the DA transporter and by inhibiting DA re-uptake. In contrast, recent studies indicate that AMPH decreases stimulation-dependent vesicular DA release. One candidate mechanism for this effect is the AMPH-mediated redistribution of DA from vesicles to the cytosol. In addition, the inhibition of stimulation-dependent release may occur because of D2 autoreceptor activation by DA that is released via reverse transport. We used the D2 receptor antagonist sulpiride and mice lacking the D2 receptor to address this issue. To evaluate carefully AMPH effects on release and uptake, we recorded stimulated DA overflow in striatal slices by using continuous amperometry and cyclic voltammetry. Recordings were fit by a random walk simulation of DA diffusion, including uptake with Michaelis-Menten kinetics, that provided estimates of DA concentration and uptake parameters. AMPH (10 μM) promoted the overflow of synaptically released DA by decreasing the apparent affinity for DA uptake ($K_m$ increase from 0.8 to 32 μM). The amount of DA released per pulse, however, was decreased by 82%. This release inhibition was prevented partly by superfusion with sulpiride (47% inhibition) and was reduced in D2 mutant mice (23% inhibition). When D2 autoreceptor activation was minimal, the combined effects of AMPH on DA release and uptake resulted in an enhanced overflow of exocytically released DA. Such enhancement of stimulation-dependent DA overflow may occur under conditions of low D2 receptor activity or expression, for example as a result of AMPH sensitization.
Introduction
Amphetamine (AMPH) is a pharmacological paradox. While it is famous for flooding the brain with dopamine (DA)—the primary driver of its reinforcing and addictive properties—it simultaneously suppresses the dopamine signals triggered by normal neuronal firing (exocytosis). We know AMPH increases extracellular DA levels by blocking re-uptake and forcing the dopamine transporter (DAT) to run in reverse. However, previous research suggested that AMPH actually decreases the amount of dopamine released during stimulation. The challenge has been "unmixing" these effects because AMPH affects both the release of DA and its removal (uptake), making standard measurements of DA "overflow" inconsistent. This study seeks to quantify how much AMPH inhibits vesicular release and identify the specific biological mechanisms, such as vesicle depletion and D2 autoreceptor feedback, driving that inhibition.
Methods
The researchers used mouse striatal slices from wild-type and D2 receptor knockout (KO) mice. They employed two complementary electrochemical techniques to monitor DA in real-time: Fast-Scan Cyclic Voltammetry (CV) for chemical identification and Continuous Amperometry for superior temporal resolution of release events.
To isolate release from uptake, the team developed a random walk simulation of DA diffusion and Michaelis-Menten uptake kinetics. By fitting experimental data to this model, they mathematically estimated the initial concentration of DA released, the maximal uptake rate ($V_{max}$), and the transporter affinity ($K_m$). To isolate the role of feedback loops, they compared wild-type mice against D2 receptor-deficient mice and used the D2 antagonist sulpiride to block natural feedback inhibition.
Results
Application of 10 μM AMPH caused a massive 82% reduction in the amount of DA released per electrical pulse in wild-type mice. This inhibition is a "one-two punch": approximately 35-59% is caused by D2 autoreceptors activated by DA "leaking" out via reverse transport, while the remainder is likely due to AMPH physically displacing DA from synaptic vesicles into the cytosol.
AMPH also drastically reduced the transporter's affinity for DA, with $K_m$ jumping from 0.8 μM to 32 μM. When D2 receptors were blocked or missing, the inhibition was significantly blunted (only 47% and 23% inhibition, respectively). Despite the massive drop in release, the total measured DA overflow can actually increase because the uptake transporters are so heavily impaired that they fail to clear even the reduced amount of released DA.
Discussion
These findings reveal that AMPH distorts the very signals it is thought to enhance. The net increase in extracellular DA observed in vivo is a result of impaired uptake masking a profound inhibition of vesicular release. This enhancement of stimulation-dependent DA overflow may be particularly relevant under conditions of low D2 receptor activity, such as those seen in amphetamine sensitization. While the in vitro nature of the study and the simulation's approximations are limitations, the model provides a robust framework for understanding the complex synaptic effects of psychostimulants and their role in addiction.
Summary updated